Highlights
- Carvedilol reduces the risk of major cirrhosis decompensation events more effectively than nadolol and propranolol.
- Meta-analyses and randomized trials reveal carvedilol’s superior reduction of hepatic venous pressure gradient (HVPG) in cirrhotic patients.
- Real-world observational studies confirm carvedilol’s protective effect against variceal hemorrhage, ascites, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS).
- Carvedilol’s dual beta- and alpha-1 adrenergic blockade provides mechanistic advantages in managing portal hypertension.
